Literature DB >> 8813547

Nicorandil suppressed ventricular arrhythmias in a canine model of myocardial ischaemia.

A Vegh1, K Györgyi, J G Papp, K Sakai, J R Parratt.   

Abstract

These experiments were designed to explore the possibility that a K+ channel opener which also donates nitric oxide to the myocardium (nicorandil) may modify ischaemia-induced ventricular arrhythmias in a large animal model. In mongrel dogs anaesthetised with chloralose-urethane and thoracotomised, a side branch of the left anterior descending artery was catheterised for the local intracoronary infusion of nicorandil (2.5 micrograms kg-1 min-1 for 20 min prior to coronary artery occlusion and then continuing throughout the 25 min occlusion period). In this dose, nicorandil had no haemodynamic effects, increased coronary blood flow by up to 16% and significantly reduced the severity of ischaemia-induced arrhythmias (e.g. from nearly 500 ventricular premature beats in the controls to 160 +/- 60 in the nicorandil group). There was a significant reduction in the number of episodes of ventricular tachycardia during the ischaemic period and a reduced incidence of ventricular fibrillation following reperfusion resulting in a 42% survival from the combined ischaemia-reperfusion insult (cf. 0% in the control; P < 0.05). The marked changes that occurred in ST-segment elevation (mapped with epicardial electrodes) and in the inhomogeneity of electrical activation within the ischaemic area in control dogs was markedly reduced in those dogs administered nicorandil. We conclude that the local intracoronary administration of nicorandil reduces the severity of both ischaemia and the life-threatening arrhythmias that result from an abrupt reduction in coronary blood flow in this canine model. Possible mechanisms include an increase in coronary blood flow, a reduction in the severity of myocardial ischaemia and an ability of the compound to "donate' nitric oxide to the ischaemic area.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8813547     DOI: 10.1016/0014-2999(96)00166-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

2.  The role of nitric oxide, superoxide and peroxynitrite in the anti-arrhythmic effects of preconditioning and peroxynitrite infusion in anaesthetized dogs.

Authors:  Attila Kiss; László Juhász; György Seprényi; Krisztina Kupai; József Kaszaki; Agnes Végh
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

3.  Role of nitric oxide in regulating cardiac electrophysiology.

Authors:  L Wang
Journal:  Exp Clin Cardiol       Date:  2001

4.  The role of mitochondrial K(ATP) channels in antiarrhythmic effects of ischaemic preconditioning in dogs.

Authors:  Agnes Végh; James R Parratt
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

5.  Modulation of gap junctions by nitric oxide contributes to the anti-arrhythmic effect of sodium nitroprusside?

Authors:  Márton Gönczi; Rita Papp; Mária Kovács; György Seprényi; Agnes Végh
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

6.  A common mechanism in the protective effects of preconditioning, cardiac pacing and physical exercise against ischemia and reperfusion-induced arrhythmias.

Authors:  Agnes Végh; James R Parratt
Journal:  Exp Clin Cardiol       Date:  2005

7.  Peroxynitrite decreases arrhythmias induced by ischaemia reperfusion in anaesthetized dogs, without involving mitochondrial KATP channels.

Authors:  A Kiss; L Juhász; I Huliák; A Végh
Journal:  Br J Pharmacol       Date:  2008-09-01       Impact factor: 8.739

8.  Effect of sodium nitrite on ischaemia and reperfusion-induced arrhythmias in anaesthetized dogs: is protein S-nitrosylation involved?

Authors:  Mária Kovács; Attila Kiss; Márton Gönczi; Gottfried Miskolczi; György Seprényi; József Kaszaki; Mark J Kohr; Elizabeth Murphy; Ágnes Végh
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.